Oral Regimens for AML Make Strides.

All-oral decitabine-cedazuridine and venetoclax regimens show promise for AML treatment, with potential improvements in patient convenience and care.

• Why it matters: Current AML treatments often require invasive intravenous or subcutaneous chemotherapy, which can be burdensome for patients. Developing effective oral options could enhance quality of life and treatment accessibility.
• What they did: Two phase I/II trials, ASCERTAIN-V and SAVE, tested the efficacy of an all-oral regimen combining decitabine-cedazuridine and venetoclax, with revumenib added in the latter study, involving multiple patients.
• The result: Findings suggest this oral combination could be a viable alternative to traditional chemotherapy, potentially transforming AML management and expanding treatment options.